Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation

The multikinase inhibitor sorafenib is under clinical investigation for the treatment of many solid tumors, but in most cases, the molecular target responsible for the clinical effect is unknown. Furthermore, enhancing the effectiveness of sorafenib using combination strategies is a major clinical c...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Int J Cancer
Autores principales: Groenendijk, Floris H, Mellema, Wouter W, van der Burg, Eline, Schut, Eva, Hauptmann, Michael, Horlings, Hugo M, Willems, Stefan M, van den Heuvel, Michel M, Jonkers, Jos, Smit, Egbert F, Bernards, René
Formato: Artigo
Lenguaje:Inglês
Publicado: Blackwell Publishing Ltd 2015
Materias:
Cancer Therapy
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4312923/
https://ncbi.nlm.nih.gov/pubmed/25080865
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.29113
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares